2nd Annual Companion Diagnostics - CDx Summit

This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development.

The summit will shed light on current challenges, best practice and offer an inside view of the future of Companion Diagnostics. We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in Companion Diagnostics landscape.

Key Practical Learning Points of the Summit:

  • What is the future of CDx & CoDx in an age of personalized healthcare?
  • Leveraging your company perspectives VS the latest trends in CDx & CoDx towards applications for new and potential biomarker-driven therapies
  • Creating a successful roadmap for CDx adoption in oncology and beyond
  • Building effective risk-mitigating strategies for CDx & Drug co-development: from novel biomarkers discovery to regulatory; reimbursement; commercialization for better patient-centered health & economic outcomes
  • Harmonizing partnerships in achieving a fitting match of tech science advancements vs CDx & novel therapies development to accelerate breakthroughs in an era of precision medicine

Who Should Attend: 

CEOs, Companion Diagnostics Vice-Presidents, Directors, Chief Medical Officers, Including:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Clinical Trials
  • Worldwide Regulatory Strategy
  • Corporate Development & Ventures
  • Oncology
  • Genomics
  • Drug Development

 From Industries Including: 

  • Pharmaceutical
  • Biotechnology
  • Medical Devices
  • Research Institutes
  • Testing Laboratories
  • CD Entities
  • Consultancy